Targeting Tumor Cells by Enhancing Radiation Sensitivity

Genes Chromosomes and Cancer

Volumn 38, Issue 4, 2003, Pages 330-338

  McKenna, W Gillies ^a   Muschel, Ruth J ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

BIOLOGICAL MODEL; CANCER CONTROL; CANCER RADIOTHERAPY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE MUTATION; GENE TARGETING; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOSENSITIVITY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR CELL;

ANIMALS; HUMANS; MUTATION; NEOPLASMS; RADIATION TOLERANCE;

ANIMALIA;

EID: 0344586930     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.10296     Document Type: Review

References (77)

1. Ader I, Toulas C, Dalenc F, Delmas C, Bonnet J, Cohen-Jonathan E, Favre G. 2002. RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death. Oncogene 21:5998-6006.
2. Arase Y, Hiwasa T, Hasegawa R, Nomura J, Ito H, Suzuki N. 2000. Prevention of v-Ha-Ras-dependent apoptosis by PDGF coordinates in phosphorylation of ERK and Akt. Biochem Biophys Res Commun 267:33-39.
3. Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG. 1996. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res 56:1727-1730.
4. Bernhard EJ, McKenna WG, Hamilton AD, Sebti SM, Qian Y, Wu JM, Muschel RJ, 1998. Inhibiting Ras prenylation Jncreases the radiosensitivity of human tumor cell lines wich activating mutations of ras oncogenes. Cancer Res 58:1754-1761.
5. Bernhard EJ, Muschel RJ, Cohen-Jonachan E, Favre G, Hamilton AD, Sebti SM, McKenna WG, 2000a. Prenykransferase inhibitors as radiosensitizers. Totowa, NJ: Humana Press.
6. Bernhard EJ, Stanbridge EJ, Gupta S, Gupta AK, Soto D, Bakanauskas VJ, Cerniglia GJ, Muschel RJ, McKenna WG. 2000b. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 60:6597-6600.
7. Bonner JA, De Los Santos J, Waksal HW, Needle MN, Trummel HQ, Raisch KP. 2002. Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin Radiat Oncol 12:11-20.
8. Brognard J, Clark AS, Ni Y, Dennis PA. 2001. Akt/protein kinase B is constitutively active in non-small cell lung cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61:3986-3997.
9. Carpenter CL, Cantley LC, 1996. Phosphoinositide kinases. Curr Opin Cell Biol 8:153-158.
10. Chan TO, Rodeck U, Chan AM, Kimmelman AC, Rittenhouse SE, Panayotou G, Tsichlis PN. 2002. Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit, Cancer Cell 1:181-191.
11. Coffer PJ, Jin J, Woodgett JR. 1998. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 335:1-13.
12. Cohen-Jonathan E, Muschel RJ, Gillies McKenna W, Evans SM, Cerniglia G, Mick R, Kusewitt D, Sebti SM, Hamilton AD, Oliff A, Kohl N, Gibbs JB, Bernhard EJ. 2000. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res 154:125-132.
13. Delmas C, Heliez C, Cohen-Jonathan E, End D, Bonnet J, Favre G, Toulas C. 2002. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int J Cancer 100:43-48.
14. Downward J. 1998. Ras signalling and apoptosis. Curr Opin Genet Dev 8:49-54.
15. Downward J, Parker P, Waterfield MD. 1984. Autophosphorylation sites on the epidermal growth factor receptor. Nature 311:483-485.
16. Druker BJ. 2002, STI571 (Gleevec) asa paradigm for cancer therapy. Trends Mol Med 8:S14-18.
17. Elion EA. 1998. Routing MAP kinase cascades. Science 281:1625-1626.
18. FitzGerald TJ, Daugherty C, Kase K, Rothstein LA, McKenna M, Greenberger JS. 1985. Activated human N-ras oncogene enhances x-irradiation repair of mammalian cells in vitro less effectively at low dose rate. Implications for increased therapeutic ratio of low dose rate irradiation. Am J Clin Oncol 8:517-522.
19. Gire V, Marshall C, Wynford-Thomas D. 2000, PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS. Oncogene 19: 2269-2276.
20. Girinsky T, Lubin R, Pignon JP, Chavaudra N, Gazeau J, Dubray B, Cosset JM, Socie G, Fertil B. 1992. Predictive value of in vitro radiosensitivity parameters in head and neck cancers and cervical carcinomas: preliminary correlations with local control and overall survival. Int J Radiat Oncol Biol Phys 25:3-7.
21. Grana TM, Rusyn EV, Zhou H, Sartor CI, Cox AD. 2002. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res 62:4142-4150.
22. Grandis J, Melhem M, Gooding W, Day R, Holst V, Wagener M, Drenning S, Tweardy D. 1998. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. JNCI Cancer Spectrum 90:824-832.
23. Gupta AK, Bernhard EJ, Bakanauskas VJ, Wu J, Muschel RJ, McKenna WG. 2000. RAS-mediated radiation resistance is not linked to MAP kinase activation in two bladder carcinoma cell lines. Radiat Res 154:64-72.
24. Gupta AK, Bakanauskas VJ, Cerniglia GJ, Cheng Y, Bernhard EJ, Muschel RJ, McKenna WG. 2001. The Ras radiation resistance pathway. Cancer Res 61:4278-4282.
25. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, Machtay M, Rosenthal DI, Bakanauskas VJ, Cerniglia GJ, Bernhard EJ, Weber RS, Muschel RJ. 2002. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 8:885-892.
26. Hagan M, Wang L, Hanley JR, Park JS, Dent P. 2000. Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiat Res 153:371-383.
27. Hahn SM, Bernhard EJ, Regine W, Mohiuddin M, Haller DG, Stevenson JP, Smith D, Pramanik B, Tepper J, DeLaney TF, Kiel KD, Morrison B, Deutsch P, Muschel RJ, McKenna WG. 2002. A phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin Cancer Res 8:1065-1072.
28. Harari PM, Huang SM. 2001a. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49:427-433.
29. Harari PM, Huang SM. 2001b. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 11:281-289.
30. Harari PM, Huang SM. 2002. Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development. Semin Radiat Oncol 12:21-26.
31. Herbst RS, Kim ES, Harari PM. 2001. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 1:719-732.
32. Howard A, Pelc SR. 1983. Synthesis of deoxyribonucleic acid in normal and irradiated cells and its relation to chromosome breakage. Heredity 6:261-273.
33. Huang SM, Li J, Harari PM. 2001. Monoclonal antibody blockade of the epidermal growth factor receptor in cancer therapy. Cancer Chemother Biol Response Modif 19:339-352.
34. Jaumot M, Yan J, Clyde-Smith J, Sluimer J, Hancock JF. 2002. The linker domain of the Ha-Ras hypervariable region regulates interactions with exchange factors, Raf-1 and phosphoinositide 3-kinase. 277:272-278.
35. Jeong H, Mason SP, Barabasi AL, Oltvai ZN. 2001. Lethality and centrality in protein networks. Nature 411:41-42.
36. Kasid U, Pfeifer A, Weichselbaum RR, Dritschilo A, Mark GE. 1987, The raf oncogene is associated with a radiation-resistant human laryngeal cancer. Science 237:1039-1041.
37. Kasid U, Pfeifer A, Brennan T, Beckett M, Weichselbaum RR, Dritschilo A, Mark GE. 1989a. Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science 243:1354-1356.
38. Kasid U, Weichselbaum R, Brennan T, Mark G, Dritschilo A. 1989b. Sensitivities of NIH/3T3-derived clonal cell lines to ionizing radiation: significance for gene transfer studies, Cancer Res 49: 3396-3400.
39. Kasid U, Pirollo K, Dritschilo A, Chang E. 1993. Oncogenic basis of radiation resistance. Adv Cancer Res 61:195-233.
40. Kasid U, Suy S, Dent P, Ray S, Whiteside TL, Sturgill TW. 1996. Activation of Raf by ionizing radiation, Nature 382:813-816.
41. Kies NIS, Harari PM. 2002. Cetuximab (Imclone/Merck/Bristol-Myers Squibb). Curr Opin Investig Drugs 3:1092-1100.
42. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. 2000. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77:25-79.
43. Knudson AG, Jr. 1971. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:890-823.
44. Knudson AG, Jr. 1975. The genetics of childhood cancer. Cancer 35:1022-1026.
45. Krasilnikov M, Adler V, Fuchs SY, Dong Z, Haimovitz-Friedman A, Herlyn M, Ronai Z. 1999. Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. Mol Carcinog 24:64-69.
46. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
47. Ling CC, Endlich B. 1989. Radioresistance induced by oncogenic transformation. Radiat Res 120:267-279.
48. Maehama T, Dixon JE. 1998. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273:13375-13378.
49. McKenna WG, Weiss MA, Bakanauskas VJ, Sandler H, Kelsten M, Biaglow J, Endlich B, Ling C, Muschel RJ. 1990a. The role of the Hras oncogene in radiation resistance and metastasis. Int J Rad Onc Biol Phys 18:849-860.
50. McKenna WG, Weiss MC, Endlich B, Ling CC, Bakanauskas VJ, Kelsten ML, Muschel RJ. 1990b. Synergistic effect of the v-myc oncogene with H-ras on radioresistance. Cancer Res 50:97-102.
51. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z. 2000. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701-708.
52. Miller AC, Kariko K, Myers CE, Clark EP, Samid D. 1993. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int J Cancer 53:302-307.
53. Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin RJ, Hamm H, Lindboe CF, Fryns JP, Sijmons RH, Woods DG, Mariman EC, Padberg GW, Kremer H. 1997. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 6:1383-1387.
54. Nelen MR, Kremer H, Konings IB, Schoute F, van Essen AJ, Koch R, Woods CG, Fryns JP, Hamel B, Hoefsloot LH, Peeters EA, Padberg GW. 1999. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 7:267-273.
55. Nicholson KM, Anderson NG. 2002. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14:381-395.
56. O'Rourke DM, Kao GD, Singh N, Park B-W, Muschel RJ, Wu C-j, Greene MI. 1998. Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. PNAS 95:10842-10847.
57. Prior IA, Hancock JF. 2001. Compartmentalization of Ras proteins. 114:1603-1608.
58. Prior IA, Harding A, Yan J, Sluimer J, Parton RG, Hancock JF. 2001. GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. 3:368-375.
59. Rait A, Pirollo K, Will DW, Peyman A, Rait V, Uhlmann E, Chang EH. 2000. 3′-End conjugates of minimally phosphorothioate-protected oligonucleotides with 1-O-hexadecylglycerol: synthesis and anti-ras activity in radiation-resistant cells. Bioconjug Chem 11: 153-160.
60. Ravasz E, Barabasi AL. 2003. Hierarchical organization in complex networks. Phys Rev E Stat Nonlin Soft Matter Phys 67:026112.
61. Reuther GW, Der CJ. 2000. The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr Opin Cell Biol 12:157-165.
62. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW. 2001. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19:3234-3243.
63. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J. 1994. Phosphatidylinositol-3-OH kinase as a direct target of Res. Nature 370:527-532.
64. Russell JS, Lang FF, Huet T, Janicot M, Chada S, Wilson DR, Tofilon PJ. 1999. Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment. 59:5239-5244.
65. Russell JS, Raju U, Gumin GJ, Lang FF, Wilson DR, Huet T, Tofilon PJ. 2002. Inhibition of radiation-induced nuclear factor-kappaB activation by an anti-Ras single-chain antibody fragment: lack of involvement in radiosensitization. Cancer Res 62:2318-2326.
66. Shao X, Tandon R, Samara G, Kanki H, Yano H, Close LG, Parsons R, Sato T. 1998. Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. Int J Cancer 77:684-688.
67. Sheridan MT, O'Dwyer T, Seymour CB, Mothersill CE. 1997. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig 5:180-186.
68. Shin D, Ro J, Hong W, Hittelman W. 1994. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54:3153-3159.
69. Sklar MD. 1988. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 239:645-647.
70. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L, Khuri FR. 2002. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8: 1178-1184.
71. Testa JR, Bellacosa A. 2001. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98:10983-10985.
72. Tezuka M, Watanabe H, Nakamura S, Yu D, Aung W, Sasaki T, Shibuya H, Miura M. 2001. Antiapoptotic activity is dispensable for insulin-like growth factor I receptor-mediated clonogenic radioresistance after gamma-irradiation. Clin Cancer Res 7:3206-3214.
73. Van Meer G. 2002. Cell biology: the different hues of lipid rafts. Science 296:855-857.
74. West CM, Davidson SE, Hendry JH, Hunter RD. 1991. Prediction of cervical carcinoma response to radiotherapy. Lancet 338:818.
75. West CM, Davidson SE, Roberts SA, Hunter RD. 1993. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix. Br J Cancer 68:819-823.
76. West CM, Davidson SE, Burt PA, Hunter RD. 1995. The intrinsic radiosensitivity of cervical carcinoma: correlations with clinical data. Int J Rad Onc 31:841-846.
77. Zacharias DA, Violin JD, Newton AC, Tsien RY. 2002. Partitioning of lipid-modified monomeric GFPs into membrane microdomains of live cells. Science 296:913-916